Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 2:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 11,571 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: CHRONIC DISEASE Clear all

Conditions: Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Interventions: Benralizumab Arm A, Benralizumab Arm B, Benralizumab Arm C, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 2,255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 151
States / cities: Birmingham, Alabama • Gulf Shores, Alabama • Montgomery, Alabama + 127 more

Conditions: Secondary Hyperparathyroidism, Chronic Kidney Disease
Interventions: Cinacalcet, active vitamin D analogue; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Lynchburg, Virginia

Conditions: Gastrointestinal Diseases
Interventions: Observational; Other
Lead sponsor: Target PharmaSolutions, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 500,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2037
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Deficiency of Vitamin D3, COPD
Interventions: Cholecalciferol, multivitamin, Placebo; Dietary Supplement
Lead sponsor: University of Pittsburgh; Other
Eligibility: 50 Years to 85 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Migraine
Interventions: CVT-427 (zolmitriptan inhalation powder); Drug
Lead sponsor: Acorda Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 3
States / cities: North Dartmouth, Massachusetts • Lincoln, Nebraska • Dallas, Texas

Conditions: Leukemia, Lymphoma
Interventions: asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, doxorubicin hydrochloride, etoposide, ifosfamide, mercaptopurine, methotrexate, prednisone, vincristine sulfate, conventional surgery, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1992 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Postherpetic Neuralgia
Interventions: T-62; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 8
States / cities: Bradenton, Florida • Naples, Florida • New Port Richey, Florida + 5 more

Conditions: End-Stage Renal Disease, Gut Microbiome Dysbiosis
Interventions: p-inulin; Dietary Supplement
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 85 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Boston, Massachusetts • Nashville, Tennessee + 1 more

Conditions: Diabetics Without Symptoms of Gastroparesis, Diabetic Gastroparesis, Idiopathic Gastroparesis, Total or Partial Gastrectomy, Chronic Nausea, Functional Dyspepsia
Interventions: magnetogastrogram; Diagnostic Test
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 12 Years to 80 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2021
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Tonsillectomy, Tonsillitis Chronic, Hemorrhage, Postoperative Pain, Postoperative Hemorrhage, Surgery--Complications, Otorhinolaryngologic Diseases
Interventions: BiZact, Standard of care; Device · Procedure
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Up to 18 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Graft Versus Host Disease, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: thalidomide; Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 3 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2002
U.S. locations: 10
States / cities: Little Rock, Arkansas • Kansas City, Kansas • New Orleans, Louisiana + 6 more

Conditions: Chronic Disease, Infectious Disorder
Interventions: Biospecimen Collection, Medical Chart Review, Questionnaire Administration; Procedure · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2029
U.S. locations: 1
States / cities: Duarte, California

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Home Automated Telemanagement (HAT); Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Chronic Viral Hepatitis, Hepatitis B Infection
Interventions: Interview, Biospecimen Collection, Electronic Health Record Review; Other · Procedure
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 365 participants
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Stroke, Cerebral Palsy, Healthy
Interventions: Rehab in a Crate System; Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Chronic Pain, Musculoskeletal Pain, Musculoskeletal Pain Disorder
Interventions: Empowered Relief, Move to Health, Usual Care as determined by primary care provider; Behavioral · Other
Lead sponsor: Brooke Army Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 608 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 5
States / cities: Fairbanks, Alaska • Schofield Barracks, Hawaii • San Antonio, Texas + 1 more

Conditions: Chronic Idiopathic Urticaria
Interventions: Placebo, Omalizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 36
States / cities: La Jolla, California • Los Angeles, California • Redwood City, California + 31 more

Conditions: Chronic Illness
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Glen Burnie, Maryland

Conditions: Chronic Sinus Disease, Surgery
Interventions: PuraSinus, Bioresorbable Nasal Dressing; Device
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Chronic Pancreatitis
Interventions: Questionnaires; Behavioral
Lead sponsor: Methodist Health System; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Dry Eyes Chronic
Interventions: Intense Pulsed Light Therapy, Sham Treatment; Device · Procedure
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Autoimmune Liver Disease, Liver Transplant Disorder, Autoimmune Hepatitis, Primary Sclerosing Cholangitis, End Stage Liver DIsease, Cirrhosis, Liver
Interventions: Siplizumab; Drug
Lead sponsor: Elizabeth C. Verna; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: ESRD
Interventions: anakinra, actos, placebo; Drug · Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 21 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Anemia, Iron-Deficiency, Kidney Failure, Chronic
Interventions: Sodium Ferric Gluconate complex in sucrose, Ferrous sulfate tablets; Drug
Lead sponsor: Watson Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 23
States / cities: Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 20 more

Search by objective public record fields.

Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History

Trial to Optimize Mineral Outcomes in Dialysis Patients

An Observational Study of Patients With Chronic Gastrointestinal Disease

The Pittsburgh Vitamin D Study: Vitamin D Supplementation in Vitamin D-deficient Subjects at Risk of Lung Cancer

A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder

Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia and Diffuse Non-Hodgkin's Lymphoma

A Study to Determine if an Investigational Pain Medicine Provides Relief of Chronic Pain After a Shingles Outbreak

Gut Microbiome and p-Inulin in Hemodialysis

Biomagnetic Characterization of Gastric Dysrhythmias III

BiZact Tonsillectomy in the Pediatric Population

Thalidomide in Treating Patients With Chronic Graft-Versus-Host Disease Following Bone Marrow Transplant

Biospecimen Analysis in Detecting Chemical Concentrations in Patients With Chronic or Infectious Diseases Receiving Meditations

Effectiveness of Home Automated Telemanagement in Chronic Obstructive Pulmonary Disorder

Social-environmental, Psychosocial, Behavioral, Clinical and Biological Drivers of Disparities in Liver Disease Progression Among Korean American With Chronic Hepatitis B Infection

Design of an Affordable Gym for Post Stroke Rehabilitation

The PROmoting Pain Self-Management (PROs) Trial: Holistic Pain Care in the Military Health System

A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)

Structuring the Integration of Care Management Services For Medicaid Enrollees Recipients With Chronic Illness, Substance Abuse Problems and Possible Psychiatric Disorders

Efficacy of PuraSinus Versus Bioresorbable Nasal Dressings

Validation of COMPAT-SF Spanish Translation

Intense Pulsed Light Study for Dry Eye Disease

A Study of SIPLIZUMAB in AILD and LT Patients

Nutrition, Inflammation and Insulin Resistance in End Stage Renal Disease-Aim 2

Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients Receiving Erythropoietic Agents